Coherus Biosciences Inc [NASDAQ: CHRS] loss -2.29% or -0.03 points to close at $1.28 with a heavy trading volume of 4209105 shares.
The daily chart for CHRS points out that the company has recorded -22.89% loss over the past six months.
If we look at the average trading volume of 5.05M shares, CHRS reached to a volume of 4209105 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Coherus Biosciences Inc [CHRS]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CHRS shares is $7.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CHRS stock is a recommendation set at 1.33. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
UBS have made an estimate for Coherus Biosciences Inc shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 16, 2024. While these analysts kept the previous recommendation, Robert W. Baird raised their target price to Outperform. The new note on the price target was released on November 17, 2023, representing the official price target for Coherus Biosciences Inc stock.
The Average True Range (ATR) for Coherus Biosciences Inc is set at 0.14, with the Price to Sales ratio for CHRS stock in the period of the last 12 months amounting to 0.49.
Trading performance analysis for CHRS stock
Coherus Biosciences Inc [CHRS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -12.33. With this latest performance, CHRS shares dropped by -13.51% in over the last four-week period, additionally sinking by -22.89% over the last 6 months – not to mention a drop of -50.39% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CHRS stock in for the last two-week period is set at 39.69, with the RSI for the last a single of trading hit 30.59, and the three-weeks RSI is set at 44.79 for Coherus Biosciences Inc [CHRS]. The present Moving Average for the last 50 days of trading for this stock 1.3541, while it was recorded at 1.3440 for the last single week of trading, and 1.4738 for the last 200 days.
Coherus Biosciences Inc [CHRS]: A deeper dive into fundamental analysis
Coherus Biosciences Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.09 and a Current Ratio set at 1.25.
An analysis of Institutional ownership at Coherus Biosciences Inc [CHRS]
There are presently around $69.50%, or 70.48%% of CHRS stock, in the hands of institutional investors. The top three institutional holders of CHRS stocks are: BLACKROCK INC. with ownership of 11.75 million shares, which is approximately 10.4236%. VANGUARD GROUP INC, holding 10.6 million shares of the stock with an approximate value of $$18.34 million in CHRS stocks shares; and VANGUARD GROUP INC, currently with $$17.99 million in CHRS stock with ownership which is approximately 9.224%.
